Key statistics
On Friday, BeOne Medicines AG (49BA:MUN) closed at 294.00, -10.37% below its 52-week high of 328.00, set on Nov 13, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 294.00 |
|---|---|
| High | 294.00 |
| Low | 294.00 |
| Bid | 290.00 |
| Offer | 294.00 |
| Previous close | 296.00 |
| Average volume | 12.00 |
|---|---|
| Shares outstanding | 118.51m |
| Free float | 116.74m |
| P/E (TTM) | 664.85 |
| Market cap | 42.71bn USD |
| EPS (TTM) | 0.5205 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 07:03 GMT.
More ▼
Press releases
- BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
- BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
- ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
- BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
- BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
- BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
- Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
- U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
- Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
More ▼
